期刊
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
卷 32-33, 期 -, 页码 95-102出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2018.05.016
关键词
IL-23; Monoclonal antibody anti-IL23; Th17 cell pathway cytokines; Ulcerative colitis; Crohn's disease; Inflammatory bowel disease
资金
- Nikkiso Europe
- Janssen
- Pfizer
- MSD
- Abbvie
- Sofar
A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis factor (TNF) drugs and vedolizumab, or lose response over time. Hence the continuing need to find new therapeutic strategies and novel drugs to control this chronic debilitating disease. Increased levels of interleukin (IL)-23 and T helper (Th) 17 cell cytokines have been found in intestinal mucosa, plasma, and serum of patients with inflammatory bowel disease (IBD). IL23-blocking has been shown to reduce the severity of inflammation in experimental colitis. Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD). This review aims to discuss the available data on IL-23 and Th17 cell pathways in UC, in order to define the role of IL-23 as possible target for the treatment of UC. (C) 2018 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据